血髓氧化酶与炎症和糖尿病状况在HFpEF中的关联
Sibille Lejeune1, Audrey Ginion1, Nassiba Menghoum1
1Division of Cardiology, Department of Cardiovascular Diseases, Cliniques Universitaires St. Luc and Pôle de Recherche Cardiovasculaire (CARD), Institut de Recherche Expérimentale et Clinique (IREC), Université Catholique de Louvain, 1200 Brussels, Belgium.
Reviews in cardiovascular medicine
|July 30, 2024
概括
患有保留喷射分数 (HFpEF) 的心力衰竭患者表现出较高的髓氧化酶 (MPO) 水平,这与炎症和氧化应激有关. 在HFpEF中,高MPO与特定的临床因素相关,但与血管度无关.
科学领域:
- 心血管医学 心血管医学
- 生物标志物 生物标志物
- 炎症和氧化应激的作用
背景情况:
- 炎症和氧化应激与心力衰竭有关,心力衰竭的病理生理学与保存的喷射分数 (HFpEF) 有关.
- 骨髓氧化酶 (MPO) 弥合了氧化应激和炎症,成为潜在的治疗点.
- 内皮功能障碍是HFpEF发育的一个关键特征.
研究的目的:
- 为了比较HFpEF患者和老年对照之间的MPO水平.
- 在HFpEF中确定与MPO水平升高相关的临床特征.
- 评估HFpEF中MPO水平和血管功能之间的关系.
主要方法:
- 观察性队列研究,包括55名HFpEF患者和18名对照.
- 使用ELISA对MPO水平的评估.
- 通过有效动脉弹性 (Ea) 和外围动脉度计 (EndoPAT) 评估血管功能.
主要成果:
- 与对照组相比,HFpEF患者的MPO水平显著更高 (p=0.026).
- MPO水平与炎症标志物 (CRP,中性粒细胞与淋巴细胞的比率) 和扩张功能障碍指标 (NT-proBNP,E/e) 相相关.
- 在HFpEF中较高的MPO水平与男性性别和糖尿病有关,但与内皮功能减少或血管硬性增加无关.
结论:
- 在HFpEF中MPO水平升高反映了白细胞激活和氧化应激.
- 在HFpEF中,高MPO与男性性别,糖尿病和腹功能障碍有关.
- 该研究没有证明MPO相关的氧化应激和血管硬之间存在联系.
相关概念视频
01:17Pathophysiology of Heart Failure
Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
01:27Heart Failure I: Introduction
Heart failure refers to a clinical syndrome caused by structural or functional cardiac disorders that prevent the heart from pumping an adequate amount of blood to meet the body's metabolic needs. This condition often arises from myocardial infarction or ischemia, leading to decreased cardiac output, reduced tissue perfusion, impaired gas exchange, fluid volume imbalance, and decreased functional ability.Heart failure can result from disruptions in the mechanisms that regulate cardiac output...
01:29Heart Failure II: Pathophysiology
Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
01:26Heart Failure III: Clinical Manifestations
Heart failure (HF) manifests primarily as dyspnea, fatigue, and fluid retention, resulting in peripheral and pulmonary edema. Symptoms may vary depending on which ventricle is more affected, left or right.Left-Sided Heart FailureAlso known as left ventricular failure, this condition results from the left ventricle's inability to fill or eject sufficient blood into the systemic circulation. It leads to pulmonary congestion, which occurs when the left ventricle fails to eject blood effectively...
01:30Heart Failure V: Medical Management
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
01:22Heart Failure VI: Adjunct Therapies
Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.